*Sponsored
Krypton Street Initiates Coverage On Elicio Therapeutics (Nasdaq: ELTX) Starting This Morning—Tuesday, August 12, 2025
Here's Why…
Analyst Target Raised To $13 By H.C. Wainwright's Robert Burns, Which Suggests Over 50% Potential Upside From (ELTX)'s Recent $8.58 Range.
Fewer Than 10.5M Shares In (ELTX)'s Public Float Could Amplify The Potential For Big Swings If Demand Begins To Shift.
Over 40% Of (ELTX) Is Held By Company Insiders, Reflecting Strong Internal Alignment.
(ELTX) Is Triggering 11 Bullish Signals On Barchart And Trending Above Or Near Key Moving Averages.
Take A Look At (ELTX) While It's Still Early…
August 12, 2025
Early Coverage | See Why (ELTX) Just Hit Our Morning Watchlist Dear Reader, The cancer immunotherapy market is not just expanding — it's accelerating toward what could be one of the fastest growth phases in its history. Analysts project the global cancer immunotherapy market will surge from about $136B in 2025 to more than $338B by 2034 — an approximate 148% increase in less than a decade. In the U.S., the growth curve is even steeper, from $40B in 2025 to roughly $106B by 2034, up about 165%. Now, imagine a Nasdaq-listed company that's tightly held, insider-aligned, and developing a technology platform built to target some of the toughest cancers known today. That company is Elicio Therapeutics (Nasdaq: ELTX). Why This Setup Stands Out
- Tight Supply: Less than 10.5M shares in the public float.
- Insider Alignment: Over 40% insider ownership (according to Yahoo).
- Technical Strength: According to Barchart's Technical Opinion tool, (ELTX) is currently triggering 11 bullish signals across short-, medium-, and long-term indicators — and is trending above or near several key moving averages.
- Analyst Target Increase: Robert Burns of H.C. Wainwright recently raised his target from $10 to $13 — suggesting over 50% upside potential from the recent $8.58 range.
When supply is this tight and insiders are this committed, the potential for momentum can build quickly if attention starts to shift. What Elicio Therapeutics (Nasdaq: ELTX) is Building
Elicio Therapeutics (Nasdaq: ELTX)'s focus is on cancers driven by mutations in the KRAS gene, which are found in roughly one in four solid tumors. Its lead program, ELI-002, is designed as an off-the-shelf vaccine to train the immune system to recognize and destroy cancer cells with these mutations. This approach could offer key advantages over personalized vaccines, including: - Rapid delivery to patients at high risk
- Lower manufacturing costs
- Commercial scalability from the outset
The Platform Advantage
At the center of (ELTX)'s innovation is its Amphiphile (AMP) technology — a delivery system that transports cancer-fighting agents directly to the lymph nodes, the "command center" of the immune system. By binding to albumin at the injection site, AMP-enabled treatments travel naturally through the lymphatic system, potentially enhancing immune precision and durability compared to conventional methods. Clinical Progress & Pipeline Reach ELI-002 is advancing through mid-stage trials, with a final disease-free survival readout from its Phase 2 AMPLIFY-7P study expected in Q4 2025. The Independent Data Monitoring Committee has already recommended continuing the trial without modifications, confirming a favorable safety profile to date. Beyond its lead program, Elicio is developing two additional AMP-based vaccines: - ELI-007 — targeting BRAF-driven cancers
- ELI-008 — addressing p53 hotspot mutations
This multi-program approach keeps the platform positioned for expansion into multiple high-prevalence cancers. Fiscal Positioning
- $10M financing in Q2 2025 extends the cash runway into Q1 2026, beyond the anticipated Phase 2 readout.
- $22.1M in cash and equivalents as of June 30, 2025.
- FDA alignment already achieved on pivotal Phase 3 trial design, with an End-of-Phase 2 meeting planned after final data.
7 Reasons Why Elicio Therapeutics (Nasdaq: ELTX) Is Topping This Morning's Watchlist—Tuesday, August 12, 2025
1. Analyst Target: H.C. Wainwright's Robert Burns recently raised his target for (ELTX) from $10 to $13, suggesting over 50% upside potential from its recent $8.58 range.
2. Limited Float: with fewer than 10.5M shares available in its public float, (ELTX) has a supply structure with the potential to witness big moves if demand begins to shift. 3.Insider Commitment: over 40% of (ELTX) is held by company insiders, according to Yahoo, signaling strong internal alignment. 4. Technical Signals: (ELTX) is triggering 11 bullish signals on Barchart's Technical Opinion tool and trending above or near several key moving averages. 5. Market Expansion: the global cancer immunotherapy market is projected to grow from about $136B in 2025 to over $338B by 2034, placing (ELTX) in a rapidly scaling sector. 6. Platform Advantage: the proprietary AMP technology from (ELTX) delivers immunotherapies directly to the lymph nodes for targeted immune activation. 7. Potential Milestones: (ELTX) is expecting final disease-free survival data from its Phase 2 AMPLIFY-7P trial in Q4 2025, a milestone that could shape its next clinical stage. With potential catalysts stacking up and a technical setup already in motion, momentum could begin building early this morning. The mix of a limited float, strong insider ownership, and upcoming data makes this one to have on the radar sooner rather than later. Take A Look At (ELTX) While It's Still Early…
With a lean public float, strong insider alignment, a recent analyst target increase, and multiple bullish technical signals, Elicio Therapeutics (Nasdaq: ELTX) is advancing in a market projected to see substantial global growth. Its proprietary AMP platform and upcoming Phase 2 data readout add further weight to its current position. We have all eyes on (ELTX) this morning. Take a look at (ELTX) while it's still early.. Watch for my next update—it could be hitting within the next 60-90 minutes. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter | 
